Targeting YTHDF2 with siRNA-loaded liposomes effectively reduces tumor growth and restores immune activity, highlighting its therapeutic potential.217 m6A modification is a dynamic regulatory mechanism that enhances VEGF-A expression, contributing to tumor progression and angiogenesis in various cancers. Here, VEGFA is linked to neoplasm.